Lipid nanoparticle-delivered Cas13b ribonucleoproteins targeting survivin overcome gemcitabine resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle (LNP)-based platform for the delivery of preassembled spCas13b ribonucleoproteins (RNPs) to achieve transient and sequence-specific RNA silencing in pancreatic cancer cells. We optimized ionizable lipid formulations for Cas13b RNP encapsulation and identified a formulation achieving approximately 80% encapsulation efficiency, with sustained colloidal stability and gene-silencing activity during seven days of storage at 4°C. LNP-delivered Cas13b RNPs efficiently silenced endogenous BIRC5 in three pancreatic cancer cell lines, reducing survivin protein levels and inducing apoptosis. In gemcitabine-resistant PANC-1 cells, BIRC5 silencing synergistically enhanced the cytotoxic effect of gemcitabine in vitro. This therapeutic combination was further evaluated in a PANC-1 xenograft model, where only the combined administration of BIRC5-targeting Cas13b RNP-LNPs and gemcitabine significantly inhibited tumor growth, without apparent systemic toxicity. Intratumoral administration also restricted nanoparticle distribution to the injected tumors. These findings establish LNP-mediated delivery of Cas13b RNPs as a new strategy for transient RNA-targeted therapy and provide proof of concept for combining survivin silencing by Cas13b with chemotherapy to address gemcitabine resistance in pancreatic cancer.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.18.767627
Primary Topic
RNA Interference and Gene Delivery
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Lipid nanoparticle-delivered Cas13b ribonucleoproteins targeting survivin overcome gemcitabine resistance in pancreatic cancer

Paola Luciani, Álvaro Somoza, Begoña Sot, Demián Pardo et al.
bioRxiv (Cold Spring Harbor Laboratory)
RNA Interference and Gene Delivery
preprint

Lipid nanoparticle-delivered Cas13b ribonucleoproteins targeting survivin overcome gemcitabine resistance in pancreatic cancer

Paola Luciani, Álvaro Somoza, Begoña Sot, Demián Pardo, María López‐Valls, Enrique Recuero, Mirentxu Santos, Diego Castaño-Esteban, Lydia Martín-Vallejo
preprint en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle (LNP)-based platform for the delivery of preassembled spCas13b ribonucleoproteins (RNPs) to achieve transient and sequence-specific RNA silencing in pancreatic cancer cells. We optimized ionizable lipid formulations for Cas13b RNP encapsulation and identified a formulation achieving approximately 80% encapsulation efficiency, with sustained colloidal stability and gene-silencing activity during seven days of storage at 4°C. LNP-delivered Cas13b RNPs efficiently silenced endogenous BIRC5 in three pancreatic cancer cell lines, reducing survivin protein levels and inducing apoptosis. In gemcitabine-resistant PANC-1 cells, BIRC5 silencing synergistically enhanced the cytotoxic effect of gemcitabine in vitro. This therapeutic combination was further evaluated in a PANC-1 xenograft model, where only the combined administration of BIRC5-targeting Cas13b RNP-LNPs and gemcitabine significantly inhibited tumor growth, without apparent systemic toxicity. Intratumoral administration also restricted nanoparticle distribution to the injected tumors. These findings establish LNP-mediated delivery of Cas13b RNPs as a new strategy for transient RNA-targeted therapy and provide proof of concept for combining survivin silencing by Cas13b with chemotherapy to address gemcitabine resistance in pancreatic cancer.

bioRxiv (Cold Spring Harbor Laboratory)
University of Bern (CH), IMDEA Nanoscience (ES)
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon